PPARγ antagonist GW9662 abolishes the promotive effect of IRF8 on lipid accumulation in hepatocytes. (IMAGE)
Caption
MPHs were transfected with Ad-GFP or Ad-IRF8 to modulate IRF8 expression and were treated with GW9662 (10 μM) to inhibit PPARγ, followed by treatment with 0.1 mM palmitic acid (PA) for 24 h. (A, B) At 48 h post-transfection, MPHs were subjected to Oil Red O staining (A), and quantification of eluted Oil Red O was performed (B). Scale bar: 100 μm. (C) The TG content of MPHs was measured. (D) The protein levels of IRF8 and PPARγ and its target genes were detected using western blots. (E) Relative mRNA levels of Irf8 and Pparγ and its target genes were quantified by quantitative PCR (n = 3 biologically independent samples). (F) The schematic overview was constructed by Biorender (https://app.biorender.com). Data are presented as mean ± standard error of the mean. p values were calculated using an unpaired two-tailed Student's t-test (B, C, E, F). PPARγ, peroxisome proliferator-activated receptor γ; IRF8, interferon regulatory factor 8; TG, triglyceride; MPHs, mouse primary hepatocytes.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND